Back to Journals » OncoTargets and Therapy » Volume 12

A pooled analysis of transarterial radioembolization with yttrium-90 microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma

Authors Zhen Y, Liu B, Chang Z, Ren H, Liu Z, Zheng J

Received 25 January 2019

Accepted for publication 15 April 2019

Published 7 June 2019 Volume 2019:12 Pages 4489—4498

DOI https://doi.org/10.2147/OTT.S202875

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jyoti Bajaj

Peer reviewer comments 3

Editor who approved publication: Professor Jianmin Xu


Yanhua Zhen, Bin Liu, Zhihui Chang, Haiyan Ren, Zhaoyu Liu, Jiahe Zheng

Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, People’s Republic of China

Purpose: The aim of this pooled analysis was to evaluate the clinical efficacy and safety of transarterial radioembolization (TARE) with yttrium-90 (90Y) microspheres for the treatment of unresectable intrahepatic cholangiocarcinoma (ICC).
Methods: We searched the Cochrane Library, Embase, PubMed, SCI with the English language from inception to October 2018. A pooled analysis was conducted using Stata software.
Results: There were 16 eligible studies included in this pooled analysis. The pooled median overall survival (OS) from 12 studies was 14.3 (95% CI: 11.9–17.1) months. Based on Response Evaluation Criteria in Solid Tumors (RECIST), no complete response was reported, and the median of partial response, stable disease and progressive disease were 11.5% (range: 4.8–35.3%), 61.5% (range: 42.9–81.3%) and 22.7% (range: 12.5–52.4%) respectively. The pooled disease control rate (DCR) from nine studies was 77.2% (95% CI: 70.2–84.2%). According to the type of microspheres, subgroup analysis was performed, the median OS in the glass microspheres group was 14.0 (95% CI: 9.1–21.4) months, and 14.3 (95% CI: 11.5–17.8) months in the resin microspheres group. The DCR was 77.3% (95% CI: 63.5–91.1%) and 77.4% (95% CI: 66.8–87.9%) in the glass and resin microspheres groups respectively. Most of the side effects reported in the included studies were mild and did not require intervention.
Conclusion: TARE with 90Y microspheres is safe and effective for patients with unresectable ICC with acceptable side effects. And it seems that the type of microsphere has no influence on therapeutic efficacy.

Keywords: transarterial radioembolization, yttrium-90 microspheres, intrahepatic cholangiocarcinoma, pooled analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]